FDA Issues EUA for Monkeypox Vaccine; CDC Follows Up with Guidance

8/10/22 – The FDA issued an emergency use authorization (EUA) for the JYNNEOS monkeypox vaccine, allowing healthcare providers to administer the vaccine by intradermal injection for individuals ages 18 years and older who are at high risk for monkeypox infection. This will result in a five-fold increase in the total number of doses available for use. Following the FDA action, the CDC released Interim Clinical Considerations for use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Monkeypox Outbreak.